<bill session="118" type="s" number="2823" updated="2025-11-19T03:14:42Z">
  <state datetime="2023-09-14">REFERRED</state>
  <status>
    <introduced datetime="2023-09-14"/>
  </status>
  <introduced datetime="2023-09-14"/>
  <titles>
    <title type="display">Securing America&#226;&#8364;&#8482;s R&amp;D Advantage Act</title>
    <title type="short" as="introduced">Securing America&#226;&#8364;&#8482;s R&amp;D Advantage Act</title>
    <title type="official" as="introduced">A bill to amend the Internal Revenue Code of 1986 to safeguard beneficial tax treatment on certain expenses from bolstering the research and development sectors in foreign entities of concern.</title>
  </titles>
  <sponsor bioguide_id="R000595"/>
  <cosponsors/>
  <actions>
    <action datetime="2023-09-14">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2023-09-14" state="REFERRED">
      <text>Read twice and referred to the Committee on Finance.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSFI" name="Senate Finance" subcommittee="" activity="Referred To"/>
  </committees>
  <relatedbills>
    <bill session="118" type="s" number="866" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Taxation"/>
  </subjects>
  <amendments/>
  <summary date="2023-09-25T15:58:33Z" status="Introduced in Senate">Securing America's R&amp;D Advantage Act

 This bill revises and expands the deductibility of research and experimental expenditures to allow immediate expensing of such expenditures. It also allows the amortization over a period of at least 60 months of certain other types of research and experimental expenditures not treated as expenses. The bill prohibits the expensing of such research and experimentation expenditures if they are conducted in North Korea, China, Russia, or Iran.

The bill increases the maximum amount eligible for the tax credit for new and small businesses and increases to 20% the rate of the credit for business startups.</summary>
</bill>
